相关实验视频
Updated: Jun 14, 2025

09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
6.6K
作为α-葡萄糖酶抑制剂的2β-乙氧铁基衍生物:合成和生物评估
Yujia Zhou1, Hengtong Qu1, Xia Qiao1
1School of Pharmacy & State Key Laboratory of Applied Organic Chemistry & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China.
Bioorganic chemistry
|September 2, 2024
概括
研究人员合成了新型肉酸衍生物作为潜在的α-葡萄糖酶抑制剂. 化合物WXC-25表现出显著的抑制活性,为管理与α-葡萄糖酶活性相关的疾病提供了有希望的治疗.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
背景情况:
- 阿尔法-葡萄糖酶是碳水化合物代谢中的一个关键酶.
- 抑制α-葡萄糖酶可以帮助管理2型糖尿病和相关的代谢障碍.
研究的目的:
- 合成和评估含有肉酸的新型2β-acetoxyferuginol衍生物作为潜在的α-葡萄糖酶抑制剂.
- 确定最强大的衍生品并阐明其作用机制.
主要方法:
- 合成了25种WXC衍生品.
- 在体外的α-葡萄糖酶抑制试验.
- 酶动力学研究.
- 光光谱学. 光光谱学.
- 分子对接模拟. 分子对接模拟.
主要成果:
- 所有25种合成衍生物都表现出显著的α-葡萄糖酶抑制活性.
- 具有4-基胺酸部分的WXC-25显示出最强大的抑制作用 (IC50 = 2.02μM),大约是阿卡尔的75倍.
- 动力学研究表明,WXC-25是一种可逆的非竞争性抑制剂.
- 光火和3D光光谱显示,WXC-25与α-葡萄糖酶结合,诱导形状变化.
- 分子对接为WXC-25和α-葡萄糖酶之间的结合相互作用提供了洞察力.
结论:
- 新型肉酸衍生物,特别是WXC-25,是α-葡萄糖酶的强有力的抑制剂.
- WXC-25代表了一种有前途的化合物,用于开发新型治疗代谢疾病的治疗剂.
- 该研究阐明了WXC-25的抑制机制和结合模式,为进一步的药物设计铺平了道路.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Sulfonylureas
197
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
197

